21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation

NCT ID: NCT01430312

Last Updated: 2020-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the irritancy potential of azelaic acid pre-foam formulation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is the standard patch test over 21 days of exposure of the test product,its vehicle and a positive as well as a negative control.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Verum

Topical application of verum (azelaic acid pre-foam formulation) on the skin

Group Type EXPERIMENTAL

azelaic acid pre-foam formulation

Intervention Type DRUG

Vehicle

Topical application of vehicle formulation (same as verum but without active drug substance) on the skin

Group Type PLACEBO_COMPARATOR

Vehicle pre-foam formulation

Intervention Type DRUG

Negative control

Topical application of distilled water (negative control) on the skin

Group Type PLACEBO_COMPARATOR

Water

Intervention Type DRUG

Positive control

Topical application of 0.5% Sodium Lauryl sulfate (positive control) on the skin

Group Type ACTIVE_COMPARATOR

Sodium lauryl sulfate

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

azelaic acid pre-foam formulation

Intervention Type DRUG

Vehicle pre-foam formulation

Intervention Type DRUG

Water

Intervention Type DRUG

Sodium lauryl sulfate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy volunteers
* male ore female subjects
* aged 18 - 65 years
* ability to understand and fulfill the study requirements

Exclusion Criteria

* affected skin in designated test area
* pregnancy or lactation
* not willing to comply with study requirements
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bayer

INDUSTRY

Sponsor Role collaborator

LEO Pharma

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Robert I. Cooper, MD

Fargo, North Dakota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1401841

Identifier Type: OTHER

Identifier Source: secondary_id

15853

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Azelaic Acid on Demodex Counts in Rosacea
NCT03035955 COMPLETED PHASE2/PHASE3